tbuckley/cabot-search huggingface dataset:
Rabies
Authors: A C Jackson, E Lopez-Corella
Journal: New England Journal of Medicine (1996)

Figure 1. Three large Negri bodies, which are eosinophilic viral inclusion bodies, can be seen in the cytoplasm of a cerebellar Purkinje cell obtained at autopsy from an eight-year-old boy in Mexico City (hematoxylin and eosin, ×2300). These viral inclusions are the pathological hallmark of rabies. The boy, bitten on the forearm by a dog that died of rabies 15 days later, had numbness and tingling at the site of the bite several days later. He presented at a clinic one month after the bite, and rabies vaccination with Fuenzalida vaccine (suckling-mouse-brain vaccine) was initiated. Two days later he was . . .
EPIDEMIOLOGY OF LYMPHOCYTIC CHORIOMENINGITIS
Authors: A G Panov, A I Shvarev
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1289: Renal cell carcinoma patients have altered HLA expression patterns which show correlations to clinical parameter
Authors: Steffen Goebel, Karen Bluemke-Anbau, Wolfgang Altermann, Udo Bilkenroth, Axel Meye, Susanne Fuessel, Astrid Kehlen, Christine Lautenschlaeger, Andres Melchior, Paolo Fornara, Helge Taubert
Journal: Cancer Research (2015)

Abstract The aim of this study was to evaluate altered HLA (Human Leukocyte Antigen) expression patterns of renal cell carcinoma (RCC) patients and healthy control persons (blood donors). Peripheral blood samples from RCC patients and from healthy controls were investigated for the incidence of HLA groups. The frequency of HLA groups was analyzed statistically and correlated with relevant clinical data. In addition, HLA subtypes were analyzed for RCC patients and for healthy blood donors. A multidimensional statistical comparison was performed. An update of the follow up for RCC patients was conducted in 2014. After following the CD45 autoMACS depletion protocol, we identified CTCs in 96 out of 233 peripheral blood samples (41%), which originated from 81 out of 154 (53%) RCC patients. We detected two HLA groups, HLA-Cw*07 and HLA-DRB1*04 that were significantly higher in healthy controls than in RCC patients (p &amp;lt; 0.05), respectively. In a Kaplan-Meier survival analysis these results were confirmed (p &amp;lt; 0.05). On the one hand, RCC patients had less alleles HLA-Cw*07 (p &amp;lt; 0.05; χ2-test) and HLA-DRB1*04 (p &amp;lt; 0.05; χ2-test) compared to healthy blood donors. On the other hand, RCC patients showed an increased occurrence of the allele HLA-Cw*12 compared to healthy blood donors. There are HLA groups that occur less often in RCC patients than in healthy controls. But it needs larger study populations and further immunological studies to investigate if special HLA-types can have a protective effect against RCC carcinogenesis. Occurrence of the alleles HLA-Cw*07, and HLA-DRB1*04 was significantly altered in RCC patients compared to healthy blood donors and may change the risk to suffer from a RCC. The integration of our results in systematic functional studies will help to earlier identify persons with an increased risk of RCC development and may have an impact in future patient care. Citation Format: Steffen Goebel, Karen Bluemke-Anbau, Wolfgang Altermann, Udo Bilkenroth, Axel Meye, Susanne Fuessel, Astrid Kehlen, Christine Lautenschlaeger, Andres Melchior, Paolo Fornara, Helge Taubert. Renal cell carcinoma patients have altered HLA expression patterns which show correlations to clinical parameter. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1289. doi:10.1158/1538-7445.AM2015-1289
PWE-134 Transjugular liver biopsy versus percutaneous liver biopsy – indications, adequacy, quality of specimens and complications
Authors: M Sehmbhi, D Doufexi, L Schoutens, C Mak, D Patch, J O'Beirne, N Davies, S Quigley, R Westbrook
Journal: Gut (2015)

<h3>Introduction</h3> Liver biopsy (LB) can be associated with adverse outcomes including technical failures, complications and inadequate tissue for histological analysis. The indication for a chosen route of LB is variable between physicians and the impact of the chosen route of LB is often unclear. <h3>Method</h3> Retrospective review of all LB performed at a UK transplant centre over a 12 month period focussing on indication and route of LB, complications, histological adequacy and variability in operator specialty and experience. <h3>Results</h3> Over the 12 month period 570 LB were performed, of which 330 were transjugular liver biopsies (TJLB) and 240 were percutaneous liver biopsies (PCLB). A LB was categorised as being histologically adequate if a histological diagnosis could be made, or if the sample met the histological standard in the literature (a 15 mm sample, with 6 or more complete portal tracts). Overall, 94% of LB were adequate based on the histological standard, and 98% allowed histological diagnosis. There were no significant differences in adequacy when comparing TJLB vs. PCLB route; however, a consultant radiologist was more likely to provide an adequate sample than a radiology registrar (p = 0.02). The overall complication rate for a liver biopsy was 5.6%. This included 8 major complications (1.4%) and 24 minor complications (4.2%). Neither the route of LB (TJLB vs. PCLB) or operator (consultant radiologist vs. radiology registrar vs. hepatologist) was significantly associated with the development of a complication. The technical failure rate of a TJLB was 4%; these included failure to puncture internal jugular vein, failure to cannulate the hepatic vein, or an unstable sheath position. There were no technical failures in the PCLB group. Screening time for a TJLB was significantly longer if the procedure was done by a radiology registrar when compared to both a hepatologist (p = 0.01) or consultant radiologist (p = 0.003). Apart from the standard indications for a TJLB we found a patient was significantly more likely to undergo a TJLB if they were post-transplant compared to pre-transplant (p = 0.001) and if the biopsy was deemed an emergency compared to an elective procedure (p = 0.001). In our cohort we identified 130 patients who had a TJLB with no indication for this procedure. <h3>Conclusion</h3> We have demonstarted that TJLB and PCLB have no significant differences in complication rates or adequacy of histological sample. Technical failure is more common in TJLB compared to PCLB. A TJLB is our preferred method in emergency cases and post-transplant patients. Further information regarding cost and patient experience is needed to identify if a change in practice is indicated. <h3>Disclosure of interest</h3> None Declared.
Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base
Authors: Shailender Bhatia, Barry E Storer, Jayasri G Iyer, Ata Moshiri, Upendra Parvathaneni, David Byrd, Arthur J Sober, Vernon K Sondak, Jeffrey E Gershenwald, Paul Nghiem
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Merkel cell carcinoma (MCC) has a high risk of recurrence after initial surgical therapy. Adjuvant radiation therapy (RT) and chemotherapy may be used to reduce the risk of locoregional and systemic recurrence, respectively, but there are conflicting data regarding their impact on survival. We performed a retrospective analysis of MCC cases from the National Cancer Data Base (NCDB) to assess whether adjuvant therapy was associated with differences in survival. Methods: Six thousand nine hundred and eight MCC patients with staging, treatment, and survival data were included. Multivariable analyses were conducted for overall survival (OS) with various treatment modalities while adjusting for prognostic variables including age, sex, comorbidities (Charlson/Deyo score), margin status, primary tumor site and size, and lymph node status. All statistical tests were two-sided. Results: For localized MCC (stage I: n = 3369, stage II: n = 1474 ), surgery plus adjuvant RT was associated with statistically significantly better OS than with surgery alone in multivariable analyses (stage I: hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.80, P < .001; stage II: HR = 0.77, 95% CI = 0.66 to 0.89, P < .001). In patients with regional nodal metastases (stage III: n = 2065 ), neither adjuvant RT nor chemotherapy was associated with statistically significantly improved or worsened OS. Conclusions: In this study of the largest MCC cohort reported to date, adjuvant RT was associated with improved OS in stages I-II MCC. Neither adjuvant RT nor chemotherapy was associated with improved OS in stage III MCC. These results, with the limitations of retrospective analyses, are consistent with earlier studies suggesting benefit with adjuvant RT but do not support the routine use of adjuvant chemotherapy in MCC.
Combined overexpression of WT1 and BAALC genes May Predict AML evolution in MDS Patients
Authors: Daniele Avenoso, Enrico De Astis, Nicoletta Colombo, Raffaella Grasso, Micaela Bergamaschi, Paola Minetto, Sara Aquino, Davide Lovera, Fabio Cruciani, Fabio Guolo, Filippo Ballerini, Marino Clavio, Letizia Canepa, Ivana Pierri, Carlo Marani, Marco Gobbi, Maurizio Miglino
Journal: Blood (2013)
Non-Hodgkin's Lymphoma Resembling Polyposis Coli
Authors: E. Rix, H.J. Bröker, R. Waldherr, A.D. Ho
Journal: Endoscopy (1986)

In a 72-year-old patient with cervical non-Hodgkin's lymphoma, colonoscopy was performed in response to a positive result of a test for occult blood (Hemoccult®). The examination revealed lesions throughout the whole of the colon, resembling polyposis coli. Histopathologic examination of the polypoid lesions disclosed an intermediate-grade non-Hodgkin's lymphoma (centrocytoma), which was identical to the histology of the cervical lymphoma. Regression of the lesions following chemotherapy, was observed by endoscopy and in the biopsy specimens. Clinical features and treatment of gastrointestinal lymphomas are discussed.
Retinoids and Cancer Prevention
Authors: M B Sporn
Journal: CA A Cancer Journal for Clinicians (1979)

Canyou givemea brief introductionto thesubjectof retinoidsand their relevance to cancer research?Retinoids are unique in that they have been shown experimen tally to be effective as cancer preventive agents.With the ex ception of steroids, there is no other class of agents like the ret inoids, in terms of their potential for influencing the develop ment of cancer at very early stages.Usually, what we label as clinical cancer is the disease that has reached its final, invasive stages.However, in many cases
Okadaic Acid: A Reversible Inhibitor of Neoplastic Transformation of Mouse Fibroblasts
Authors: L J Mordan, N M Dean, R E Honkanen, A L Boynton
Journal: Cancer Communications (1990)

Okadaic acid (OA) is a potent inhibitor of serine/threonine-specific protein phosphatases types 1 and 2A at nanomolar concentrations in cell-free assays and has tumor promoting activity in vivo. We have found that at non-toxic, nanomolar concentrations, OA concentration dependently inhibits the induction of focus-forming transformed cells by the "complete" and "two-stage" protocols in the C3H/10T1/2 mouse fibroblast transformation assay. This inhibitory effect was fully reversible upon removal of OA from the culture medium of carcinogen-treated cells, indicating that OA was not selectively toxic to initiated or transformed cells. Additional treatment with the phorbol ester tumor promoter, TPA, was required to promote the induction of transformed cells after the removal of OA in the two-stage transformation assay. At concentrations that inhibited neoplastic transformation, OA inhibited a type 2A-like phosphohistone protein phosphatase in homogenates of C3H/10T1/2 cells. It is postulated that OA inhibited an early protein phosphatase-sensitive event in the process of in vitro neoplastic transformation by C3H/10T1/2 fibroblasts and had the effect of maintaining carcinogen-treated cells in an initiated state.
Profiles of couples seeking sex therapy and marital therapy
Authors: E Frank, C Anderson, D J Kupfer
Journal: American Journal of Psychiatry (1976)

Assessment of 29 couples seeking marital therapy and 25 seeking sexual therapy at the same institution permitted the delineation of two distinct profiles. Although the two groups were similar in the degree of their sexual and marital difficulties and in demographic characteristics, the relationships of the sex therapy couples were generally characterized by satisfaction and affection, whereas those of the marital therapy couples were often antagonistic. In addition, the sex therapy couples tended to be less conservative and more thoughtful in their approach to life and their problems.
SP0086 Going West – Research Experience in the US
Authors: H. Radner
Journal: Annals of the Rheumatic Diseases (2015)

One fundamental step in a research career is going abroad at some point. Like in Plato9s Cave Allegory, leaving the comfort zone by crossing borders can broaden your horizon in diversified ways. It is an opportunity to gain technical and intellectual skills, get insight into different areas, address research questions from different perspectives and establish ongoing and future collaborations. In this presentation the personal experience of performing research in the US will be presented. Two years ago I left Austria to undergo a postdoctoral research fellowship at the Brigham and Women9s Hospital/Harvard Medical School in Boston and I will present ups and downs of working as a researcher at a world-leading University. <h3>Disclosure of Interest</h3> None declared
FRI0553 Pronostic Test in Chronic Low Back Pain Patients: Stabilisation Test
Authors: M. Norberg, L. Belgrand, M. Norberg
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Chronic low back pain has an important socio-economic burden. It is frequent but the treatment models are different. One of the most successful and well documented is the multidisciplinary approach. But which patient will respond? There are the yellow and black flags that give bad prognostic. In 2003, Hicks presented a muscular test for segmental instability. As physical decondition is frequent present, the question is if this muscular test would allow us to select the patients that would respond in a recondition program. <h3>Methods</h3> We have studied the results of 240 patients who have accomplished this interdisciplinary program, follow-up on 18 months. In the rehab program they have physical reconditioning, occupational exercises the whole in a TCC context. All patients had the Hicks Test at inclusion (predictive test to choose between surgery and conservative treatment in chronic low back pain in the 90ths) and studied its association with pain evolution, functional capacity and work capacity <h3>Results</h3> We separated the patients in 2 groups: those with a positive Hicks test and those who were negative. We observed that the 2 groups had better pain scales, but the decrease was better in the positive group, as was the work capacity at 18 months (from 39 to 52% in the negative group, against 53 to 83% in the positive group. The Oswestry functional questionnaire showed slight better results in the positive group compared with the negative, the results were the same at 18 months. <h3>Conclusions</h3> To be able to choose the patient that would respond to a multidisciplinary rehabilitation program in low back pain the long standing results would be increased by using Hicks test (stabilisation test). In fact the patients with a positive test have a better return to work, and a more better decrease in pain. <h3>References</h3> Hicks GE, Fritz JM, Delitto A, Mishock J. Interrater reliability of clinical examination measures for identification of lumbar segmental instability. Arch Phys Med Rehabil 2003;84:1858-64. <h3>Disclosure of Interest</h3> None declared
FRI0523 Clinical Value of Serum Anti-C1Q Antibodies as a Marker for Nephritis Activity in Pediatric Patients with SLE in Comparison to Anti-DSDNA
Authors: M. Helal, N.A.E.M. Hussein, M.M.E.D. El Kersh, D.M.F. Mohaseb, M.M. El Bardawil, M.M. El Sawy
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Autoantibodies against C1q (anti-C1q) have been described a lot in adult patients with systemic lupus erythromatosus (SLE), where they were strongly significant with the occurrence of severe lupus nephritis (LN). However, due to the few clinical studies held in the field of pediatric rheumatology its role has not been well determined in children with systemic lupus erythromatosus. <h3>Objectives</h3> To evaluate serum anti-C1q antibodies in pediatric systemic lupus erythromatosus (pSLE) to determine its clinical and statistical association in nephritis activity in comparison to anti-dsDNA <h3>Methods</h3> Sera from 44 pSLE patients and 30 healthy individuals were collected. Anti-C1q, Anti-dsDNA, ANA, were measured by enzyme-linked immunosorbant assays. Patient records were evaluated for clinical and laboratory associations <h3>Results</h3> Anti-C1q antibodies were more prevalent than anti-ds DNA (n=41,93.2%)in pSLE patients of the current study, which correlated significantly with proteinuria and decreased complement levels (p&lt;0.05). Anti-C1q levels were significantly elevated in patients with class III/IV nephritis compared II/V nephritis. pSLE patients with active nephritis at the time of sample collection demonstrated significantly elevated levels of anti-C1q antibodies compared to those without active nephritis. Anti-C1q antibodies were more sensitive and specific than anti-dsDNA in pSLE patients <h3>Conclusions</h3> This study indicates the importance of measuring anti-C1q antibodies in pSLE patients because elevated anti-C1q antibodies may be more indicative and specific for detecting disease activity, showing significant correlation with proteinuria and active nephritis than anti-DNA antibodies <h3>References</h3> Kozyro I, Perahud I, Sadallah S, et al. Clinical value of autoantibodies against C1q in children with glomerulonephritis. Pediatrics. 2006;117(5):1663-8 Salah M, Abdel Kader M, Abd Elaziz M, Hisham M. Role of serum anti-C1q antibodies as a biomar ker for nephritis activity in pediatric and adolescent Egyptian female patients with SLE. Expert Opin. Med. Diagn; 2012 (6):489-498 Eggert M, Zettl UK, Neeck G. Autoantibodies in autoimmune diseases. Curr Pharm Des 2010;16:1634-43. Pickering MC, Botto M. Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol 2010;6:490-3. <h3>Acknowledgements</h3> I would like to thank all my supervisors for thier expert advice and encouragement through out this study <h3>Disclosure of Interest</h3> None declared
68Ga-DOTATATE Breast Uptake and Expression in Breast Milk
Authors: Nicholas J. Forwood, Gowri L. Kanthan, Dale L. Bailey, David L. Chan, Geoffrey P. Schembri
Journal: Clinical Nuclear Medicine (2016)

The excretion of 68Ga-DOTA-Octreotate (DOTATATE) and related somatostatin analogues in breast milk has not been demonstrated. We report a case of a 34-year-old woman, 7 months postpartum and breastfeeding, who was referred for DOTATATE imaging after the diagnosis of appendiceal carcinoid and subsequent appendectomy. Prominent breast uptake was noted. A breast milk sample from the patient at 90 minutes postinjection was assayed in a gamma counter and shown to have a concentration of 5.6 Bq/g per MBq administered. The excretion of DOTATATE in breast milk is important to consider when providing radiation safety advice to breastfeeding patients.
SP0203 Non-Inferiority Studis: Sense or Non-Sense
Authors: E. Lesaffre
Journal: Annals of the Rheumatic Diseases (2015)

In the classical randomized controlled trial (RCT) the aim is to show that one treatment is superior to another. This is called the <i>superiority trial</i>. However, nowadays it often occurs that the experimental treatment is not expected to show a better efficacy, but rather aims to improve upon the current treatments in other aspects, e.g. better safety profile, easier to administer, cheaper, etc. In that case, we may wish to show that the experimental and the control treatment do not differ in efficacy but that the experimental treatment has some other advantages. A non-significant outcome of a superiority trial is, however, not a proof of equal efficacy performance. In contrast, we need to set up another clinical trial design, called the <i>non-inferiority</i> (NI) <i>trial</i>. In that case, one needs to specify upfront what is meant by "equality of efficacy", and the practical and statistical aspects of the trial may be quite different from a superiority trial. In this presentation the non-inferiority trial is contrasted to the superiority trial. Practical aspects and pitfalls when setting-up a NI trial and/or interpreting the results of a NI trial will be discussed. It is shown that NI trials pose different, and often more complex, practical problems than superiority trials. Practical recommendations for setting up a NI trial are given. <h3>Disclosure of Interest</h3> None declared